We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ZYAMIS (Veriton Pharma Pty Limited)
Product name
ZYAMIS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
194 (255 working days)
Active ingredients
midazolam maleate
Registration type
EOI
Indication
ZYAMIS (oromucosal solution), as buccal midazolam, is indicated for the treatment of generalised convulsive status epilepticus (GCSE), in those over 6 months old.